Profound Medical Corp(PRN-T)
TSX

Today's Change
Real-Time Last Update
Day Low9.22
Day High9.78
Open:9.54
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Newsfile
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
GlobeNewswire
Profound Medical Reports Strong First Quarter 2026 Financial Results
The Globe and Mail
Why this money manager is buying Pet Valu and selling Major Drilling
Jean Francois Tardif Illustration by Joel Kimmel
GlobeNewswire
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
Baystreet
Stocks in play: Profound Medical Corp.
GlobeNewswire
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
GlobeNewswire
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
INK Research
CEO buying at Profound Medical (PRN)
Company Chart of PRN
Newsfile
Upcoming Meeting Dates - March 23, 2026
GlobeNewswire
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
GlobeNewswire
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
GlobeNewswire
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
GlobeNewswire
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
GlobeNewswire
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
GlobeNewswire
Profound Medical Announces Upcoming Investor Events
GlobeNewswire
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

Profile

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.